Syngeneic mouse tumor model studies (i.e., the B16-OVA melanoma and MC38 colon cancer models) provide proof-of-principle evidence for the cancer immunotherapeutic potential of MAOIs, especially when used in combination with ICB therapies such as PD-1/PD-L1 blocking [18]. The gene discussed is PDCD1; the disease is cancer.